Barclays’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1
| Closed | -$7 | – | 5502 |
|
|
2026
Q1 | $7 | Hold |
1
| – | – | ﹤0.01% | 4985 |
|
|
2025
Q4 | $6 | Hold |
1
| – | – | ﹤0.01% | 5161 |
|
|
2025
Q3 | $4 | Hold |
1
| – | – | ﹤0.01% | 5418 |
|
|
2025
Q2 | $5 | Hold |
1
| – | – | ﹤0.01% | 5170 |
|
|
2025
Q1 | $5 | Hold |
1
| – | – | ﹤0.01% | 5192 |
|
|
2024
Q4 | $7 | Buy |
+1
| New | +$7 | ﹤0.01% | 5230 |
|
|
2024
Q3 | – | Sell |
-22
| Closed | -$133 | – | 5262 |
|
|
2024
Q2 | $131 | Sell |
22
-4,990
| -100% | -$37.9K | ﹤0.01% | 4747 |
|
|
2024
Q1 | $45.2K | Sell |
5,012
-4,792
| -49% | -$43.7K | ﹤0.01% | 4633 |
|
|
2023
Q4 | $92.9K | Buy |
9,804
+8,545
| +679% | +$75.1K | ﹤0.01% | 4653 |
|
|
2023
Q3 | $15K | Sell |
1,259
-164
| -12% | -$2.91K | ﹤0.01% | 4231 |
|
|
2023
Q2 | $34.9K | Sell |
1,423
-81,480
| -98% | -$2.12M | ﹤0.01% | 3985 |
|
|
2023
Q1 | $2.59M | Buy |
82,903
+64,154
| +342% | +$3.71M | ﹤0.01% | 1997 |
|
|
2022
Q4 | $1.32M | Buy |
18,749
+3,428
| +22% | +$254K | ﹤0.01% | 2577 |
|
|
2022
Q3 | $1.32M | Buy |
15,321
+14,918
| +3,702% | +$1.45M | ﹤0.01% | 2027 |
|
|
2022
Q2 | $33K | Sell |
403
-212
| -34% | -$18.7K | ﹤0.01% | 4206 |
|
|
2022
Q1 | $102K | Sell |
615
-3,631
| -86% | -$521K | ﹤0.01% | 3771 |
|
|
2021
Q4 | $710K | Buy |
4,246
+1,046
| +33% | +$118K | ﹤0.01% | 3023 |
|
|
2021
Q3 | $277K | Buy |
3,200
+961
| +43% | +$63.6K | ﹤0.01% | 3456 |
|
|
2021
Q2 | $122K | Sell |
2,239
-2,199
| -50% | -$125K | ﹤0.01% | 3769 |
|
|
2021
Q1 | $264K | Buy |
4,438
+1,607
| +57% | +$93.9K | ﹤0.01% | 3576 |
|
|
2020
Q4 | $148K | Sell |
2,831
-381
| -12% | -$21.2K | ﹤0.01% | 3944 |
|
|
2020
Q3 | $155K | Sell |
3,212
-180
| -5% | -$8.61K | ﹤0.01% | 4013 |
|
|
2020
Q2 | $175K | Buy |
3,392
+561
| +20% | +$28.3K | ﹤0.01% | 4164 |
|
|
2020
Q1 | $124K | Sell |
2,831
-550
| -16% | -$22.4K | ﹤0.01% | 4647 |
|
|
2019
Q4 | $135K | Buy |
3,381
+787
| +30% | +$24.2K | ﹤0.01% | 5296 |
|
|
2019
Q3 | $85K | Buy |
2,594
+90
| +4% | +$4.34K | ﹤0.01% | 5596 |
|
|
2019
Q2 | $193K | Buy |
2,504
+2,148
| +603% | +$334K | ﹤0.01% | 5138 |
|
|
2019
Q1 | $63K | Buy |
+356
| New | +$70.2K | ﹤0.01% | 5707 |
|
|
2018
Q4 | – | Sell |
-193
| Closed | -$41K | – | 7135 |
|
|
2018
Q3 | $41K | Buy |
+193
| New | +$33.7K | ﹤0.01% | 6187 |
|
Barclays's KZR Position: Q2 2026 in Review
Barclays sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 1 share — an estimated $7 sold.
Barclays first reported a position in KZR in Q3 2018 and held it in 29 quarters. The position peaked at $2.59M in Q1 2023. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Barclays reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Barclays sold 1 Kezar Life Sciences share in Q2 2026, an estimated $7.
- Barclays first reported a position in Kezar Life Sciences in Q3 2018 and held it in 29 quarters.
- Barclays's Kezar Life Sciences position peaked at $2.59M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.